Superko相关文献与解析，生知库 | 链接生命科学的每一步

Small Dense LDL: Scientific Background, Clinical Relevance, and Recent Evidence Still a Risk Even with 'Normal' LDL-C Levels

小而密低密度脂蛋白：科学背景、临床意义及最新证据即使低密度脂蛋白胆固醇水平“正常”，仍然存在风险

期刊:Biomedicines

影响因子:3.9

doi:10.3390/biomedicines10040829

Superko, Harold; Garrett, Brenda

代谢

发表日期：2022

文献求助收藏

Trends in low-density lipoprotein-cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines

2012年至2017年间低密度脂蛋白胆固醇血液值的变化趋势表明，2013年最新治疗指南的采纳速度缓慢。

期刊:Clinical Cardiology

影响因子:2.3

doi:10.1002/clc.23115

Superko, H Robert; Williams, Paul T; Dansinger, Michael; Schaefer, Ernst

代谢

发表日期：2019

文献求助收藏

Cardiovascular Risk Factor Reduction in First Responders Resulting From an Individualized Lifestyle and Blood Test Program: A Randomized Controlled Trial

通过个体化的生活方式和血液检测方案降低急救人员心血管危险因素：一项随机对照试验

期刊:Journal of Occupational and Environmental Medicine

影响因子:1.4

doi:10.1097/JOM.0000000000001490

Gill, Rosalynn; Superko, Harold Robert; McCarthy, Megan M; Jack, Kepra; Jones, Briana; Ghosh, Debanjali; Richards, Steve; Gleason, Joi A; Williams, Paul T; Dansinger, Michael

发表日期：2019

文献求助收藏

Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial

通过离子迁移率测定的致动脉粥样硬化脂蛋白亚组分与随机分配至高强度他汀类药物或安慰剂组后首次心血管事件的关系：他汀类药物用于预防的合理性：一项评估瑞舒伐他汀的干预试验（JUPITER试验）

期刊:Circulation

影响因子:38.6

doi:10.1161/CIRCULATIONAHA.115.016857

Mora, Samia; Caulfield, Michael P; Wohlgemuth, Jay; Chen, Zhihong; Superko, H Robert; Rowland, Charles M; Glynn, Robert J; Ridker, Paul M; Krauss, Ronald M

Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises

利用基因检测早期发现冠心病高危人群并监测治疗反应：挑战与前景

期刊:Current Atherosclerosis Reports

影响因子:5.2

doi:10.1007/s11883-011-0198-8

Superko, H Robert; Roberts, Robert; Agatston, Arthur; Frohwein, Stephen; Reingold, Jason S; White, Thomas J; Sninsky, John J; Margolis, Basil; Momary, Kathryn M; Garrett, Brenda C; King, Spencer B 3rd

Survival bias and drug interaction can attenuate cross-sectional case-control comparisons of genes with health outcomes. An example of the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism and coronary heart disease

生存偏倚和药物相互作用会削弱基因与健康结果之间横断面病例对照比较的结果。例如，驱动蛋白样蛋白6 (KIF6) Trp719Arg多态性与冠心病之间的关系。

期刊:BMC Medical Genetics

影响因子:

doi:10.1186/1471-2350-12-42

Williams, Paul; Pendyala, Lakshmana; Superko, Robert

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy

烟酸缓释片与辛伐他汀联合用药比阿托伐他汀单药治疗更能降低动脉粥样硬化性血脂异常。

期刊:Vascular Health and Risk Management

影响因子:2.8

doi:10.2147/VHRM.S14053

Insull, William Jr; Toth, Peter P; Superko, H Robert; Thakkar, Roopal B; Krause, Scott; Jiang, Ping; Parreno, Rhea A; Padley, Robert J

The aspirin heart disease prevention conundrum

阿司匹林预防心脏病的难题

Small Dense LDL: Scientific Background, Clinical Relevance, and Recent Evidence Still a Risk Even with 'Normal' LDL-C Levels

小而密低密度脂蛋白：科学背景、临床意义及最新证据即使低密度脂蛋白胆固醇水平“正常”，仍然存在风险

Trends in low-density lipoprotein-cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines

2012年至2017年间低密度脂蛋白胆固醇血液值的变化趋势表明，2013年最新治疗指南的采纳速度缓慢。

Cardiovascular Risk Factor Reduction in First Responders Resulting From an Individualized Lifestyle and Blood Test Program: A Randomized Controlled Trial

通过个体化的生活方式和血液检测方案降低急救人员心血管危险因素：一项随机对照试验

Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial

通过离子迁移率测定的致动脉粥样硬化脂蛋白亚组分与随机分配至高强度他汀类药物或安慰剂组后首次心血管事件的关系：他汀类药物用于预防的合理性：一项评估瑞舒伐他汀的干预试验（JUPITER试验）

Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises

利用基因检测早期发现冠心病高危人群并监测治疗反应：挑战与前景

Survival bias and drug interaction can attenuate cross-sectional case-control comparisons of genes with health outcomes. An example of the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism and coronary heart disease

生存偏倚和药物相互作用会削弱基因与健康结果之间横断面病例对照比较的结果。例如，驱动蛋白样蛋白6 (KIF6) Trp719Arg多态性与冠心病之间的关系。

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy

烟酸缓释片与辛伐他汀联合用药比阿托伐他汀单药治疗更能降低动脉粥样硬化性血脂异常。

The aspirin heart disease prevention conundrum

阿司匹林预防心脏病的难题

Small Dense LDL: Scientific Background, Clinical Relevance, and Recent Evidence Still a Risk Even with 'Normal' LDL-C Levels

小而密低密度脂蛋白：科学背景、临床意义及最新证据 即使低密度脂蛋白胆固醇水平“正常”，仍然存在风险

Trends in low-density lipoprotein-cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines

2012年至2017年间低密度脂蛋白胆固醇血液值的变化趋势表明，2013年最新治疗指南的采纳速度缓慢。

Cardiovascular Risk Factor Reduction in First Responders Resulting From an Individualized Lifestyle and Blood Test Program: A Randomized Controlled Trial

通过个体化的生活方式和血液检测方案降低急救人员心血管危险因素：一项随机对照试验

Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial

通过离子迁移率测定的致动脉粥样硬化脂蛋白亚组分与随机分配至高强度他汀类药物或安慰剂组后首次心血管事件的关系：他汀类药物用于预防的合理性：一项评估瑞舒伐他汀的干预试验（JUPITER试验）

Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises

利用基因检测早期发现冠心病高危人群并监测治疗反应：挑战与前景

Survival bias and drug interaction can attenuate cross-sectional case-control comparisons of genes with health outcomes. An example of the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism and coronary heart disease

生存偏倚和药物相互作用会削弱基因与健康结果之间横断面病例对照比较的结果。例如，驱动蛋白样蛋白6 (KIF6) Trp719Arg多态性与冠心病之间的关系。

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy

烟酸缓释片与辛伐他汀联合用药比阿托伐他汀单药治疗更能降低动脉粥样硬化性血脂异常。

小而密低密度脂蛋白：科学背景、临床意义及最新证据即使低密度脂蛋白胆固醇水平“正常”，仍然存在风险